TFC Financial Management’s Alexion Pharmaceuticals ALXN Stock Holding History

TFC Financial Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5	Closed	-$1K	–	605
2021 Q2	$1K	Hold	5	–	–	﹤0.01%	570
2021 Q1	$1K	Hold	5	–	–	﹤0.01%	562
2020 Q4	$1K	Hold	5	–	–	﹤0.01%	549
2020 Q3	$1K	Buy	+5	New	+$539	﹤0.01%	523

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

TFC Financial Management's ALXN Position: Q3 2021 in Review

TFC Financial Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 5 shares — an estimated $1K sold.

TFC Financial Management first reported a position in ALXN in Q3 2020 and held it in 4 quarters. The position peaked at $1K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

TFC Financial Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
TFC Financial Management sold 5 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1K.
TFC Financial Management first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
TFC Financial Management's Alexion Pharmaceuticals position peaked at $1K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on TFC Financial Management's 13F filing for Q3 2021, filed 2 Nov 2021.